|
Treatments ordered from least to most effective
|
Patient-level
|
Population-level (100 MDR patients)
|
Incremental cost per QALY gained (€)
|
|---|
|
Total cost, €
|
Total QALYs gained
|
Total LYG
|
Total cost, €
|
Total QALYs gained
|
Total LYG
|
Versus BR alone
|
Versus Linezolid plus BR
|
Versus delamanid plus BR
|
|---|
|
BR alone
|
60,962
|
3.68
|
4.82
|
6,096,152
|
368
|
482
|
–
|
87,484
|
38,703
|
|
Linezolid plus BR
|
80,460
|
3.91
|
5.07
|
8,045,981
|
391
|
507
|
87,484
|
–
|
2026
|
|
Delamanid plus BR
|
81,079
|
4.21
|
5.36
|
8,107,888
|
421
|
536
|
38,703
|
2026
|
–
|
|
Bedaquiline plus BR
|
85,575
|
4.79
|
5.95
|
8,557,529
|
479
|
595
|
22,238
|
5787
|
7774
|
-
BR Background Regimen, QALY Quality-Adjusted Life Year, LYG life-years gained
